Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin

References

• Cubicin summary of product characteristics 2010 Available at: www.emea.europa.eu/humandocs/Humans/EPAR/cubicin/cubicin.htm. Accessed 30 January 2011.
   Google Scholar
• Beiras-FernandezAVogtFSodianRDaptomycin: a novel lipopeptide antibiotic against Gram-positive pathogensInfect Drug Resist201039510121694898
   PubMedGoogle Scholar
• EronLJLipskyBALowDEManaging skin and soft tissue infections: expert panel recommendations on key decision pointsJ Antimicrob Chemother200352Suppl 1i3i1714662806
   PubMedGoogle Scholar
• FDAGuidance for Industry: uncomplicated and complicated skin and skin structure infections – developing antimicrobial drugs for treatment Available from: http://www.fda.org/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf. Accessed 30 January 2011.
   Google Scholar
• KiVRotsteinCBacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of careCan J Infect Dis Med Microbiol200819217318419352449
   PubMed Web of Science ®Google Scholar
• MarwickCBroomhallJMcCowanCSeverity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patientsJ Antimicrob Chemother201166238739720926396
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJMethicillin-resistant S. aureus infections amongst patients in the emergency departmentN Engl J Med2006355766667416914702
   PubMed Web of Science ®Google Scholar
• European Center for Disease Prevention and ControlAntimicrobial resistance surveillance in Europe 2009 Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC;2010. Available from: http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_annual_EARS_Net_2009.pdf. Accessed 30 January 2011.
   Google Scholar
• GemmelCGEdwardsDIFraiseAPGuidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UKJ Antimicrob Chemother200657458960816507559
   PubMed Web of Science ®Google Scholar
• LemanPMukherjeeDFlucloxacillin alone or combined with benzyl-penicillin to treat lower limb cellulitis: a randomized controlled trialEmerg Med J200522534234615843702
   PubMed Web of Science ®Google Scholar
• BoucherHMillerLGRazonableRRSerious infections caused by Methicillin-resistant Staphylococcus aureusClin Infect Dis201051Suppl 2S183S19720731576
   PubMed Web of Science ®Google Scholar
• KinneyKKTreatment of infections caused by antimicrobial-resistant Gram-positive bacteriaAm J Med Sci2010340320921720823699
   PubMed Web of Science ®Google Scholar
• ItaniKMDrydenMSBhattacharyyaEfficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureusAm J Surg2010199680481620227056
   PubMed Web of Science ®Google Scholar
• GouldFKBrindleRChadwickPRGuidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United KingdomJ Antimicrob Chemother200963584986119282331
   PubMed Web of Science ®Google Scholar
• ArbeitRDMakiDTallyFPCampanaroEEisensteinBIThe safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsClin Infect Dis200438121673168115227611
   PubMed Web of Science ®Google Scholar
• BliziotisIAPlessaEPeppasGFalagasMEDaptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: A meta-analysisAnn Pharmacother20104419710619934396
   PubMed Web of Science ®Google Scholar
• VinhDCRubinsteinELinezolid: a review of safety and tolerabilityJournal of Infection200959Suppl 1S59S7419766891
   PubMed Web of Science ®Google Scholar
• StreitJMJonesRNSaderHSDaptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organismsJ Antimicrob Chemother200453466967414985278
   PubMed Web of Science ®Google Scholar
• AnastasiouDMThorneGMLuperchioSAlderJDIn vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinuprisitn/dalfopristinInt J Antimicrob Agents200628538538817046205
   PubMed Web of Science ®Google Scholar
• AlbornWEJrAllenNEPrestonDADaptomycin disrupts membrane potential in growing Staphylococcus aureusAntimicrob Agents Chemother19913511228222871666494
   PubMed Web of Science ®Google Scholar
• HairPIKeamSJDaptomycin: A review of its use in the management of complicated skin and soft tissue infections and Staphylococcus aureus bacteraemiaDrugs200767101483151217600394
   PubMed Web of Science ®Google Scholar
• WiseRGeeTAndrewsJMDvorchikBMarshallGPharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteersAntimicrob Agents Chemother2002461313311751107
   PubMed Web of Science ®Google Scholar
• RitchieNDLoveringAMSeatonRADaptomycin in synovial fluid during treatment of methicillin-resistant Staphylococcus aureus septic arthritisJ Antimicrob Chemother20106561314131520382723
   PubMed Web of Science ®Google Scholar
• TraunmullerFSchintlerMVMetzlerJSoft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infectionsJ Antimicrob Chemother20106561252125720375031
   PubMed Web of Science ®Google Scholar
• SchrievnerCAFernandezCRodvoldKDanzigerLHDaptomycin: a novel cyclic lipopeptide antimicrobialAm J Health Syst Pharm200562111145115815914875
   PubMed Web of Science ®Google Scholar
• LiuCBayerACosgroveSEClinical practice guidelines by the Infectious Diseases Society of America for the treatment of Methicillin-Resistant Staphylococcus aureus infections in adults and childrenClin Inf Dis2011523e18e55
   PubMed Web of Science ®Google Scholar
• FowlerVGJrBoucherHWCoreyGRDaptomycin versus standard therapy for bacteraemia and endocarditis caused by Staphylococcus aureusN Engl J Med2006355765366516914701
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA drug safety communication: eosinophilic pneumonia associated with the use of Cubicin (daptomycin) Available from: www.fda.gov/drugs/drugsafety. Updated 29 July 2010. Accessed 30 January 2011.
   Google Scholar
• Abdel-RahmanSMBenzigerDPJacobsRFSingle-dose pharmacokinetics of daptomycin in children with suspected or proved Gram-positive infectionsPaediatr Infect Dis J2008274330334
   PubMed Web of Science ®Google Scholar
• SeatonRADaptomycin: rationale and role in the management of skin and soft tissue infectionsJ Antimicrob Chemother.200862Suppl 3iii15iii2318829721
   PubMed Web of Science ®Google Scholar
• Johns Hopkins POC-IT Center ABX Guide Home page on the Internet. Available from: http://hopkins-abxguide.org Accessed January 2011.
   Google Scholar
• KrigeJELindfieldKFriedrichLEffectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infectionsCurr Med Res Opin20072392147215617669231
   PubMed Web of Science ®Google Scholar
• GollnickHQuistSRFierlbeckGEfficacy and safety of daptomycin versus vancomycin or teicoplanin for the treatment of cSSTIs: a multicenter, randomised, assessor-blind trialAbstract of the 20th European Congress of Clinical Microbiology and Infectious Diseases2010 April 10–13Vienna, Austria Poster 1551.
   Google Scholar
• PertelPEEisensteinBILinkASThe efficacy and safety of daptomycin versus vancomycin for the treatment of cellulitis and erysipelasInt J Clin Pract2009633336837519222623
   PubMed Web of Science ®Google Scholar
• KatzDELindfieldKCSteenbergenJNA pilot study of high dose short duration daptomycin for the treatment of patients with complicated skin and skin-structure infections caused by Gram-positive bacteriaInt J Clinc Pract200862914551464
   Web of Science ®Google Scholar
• DavisSLMcKinnonPSHallLMDaptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomesPharmacotherapy200727121611161818041881
   PubMed Web of Science ®Google Scholar
• FigtreeMKonecnyPJenningsZGohCKrikisSAMiyakisSRisk stratification and outcome of cellulitis admitted to hospitalJ Infect201060643143920346971
   PubMed Web of Science ®Google Scholar
• LogmanJFSStephensJHaiderSComparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infectionsCurr Med Res Opin20102671565157820429820
   PubMed Web of Science ®Google Scholar
• Gonzalez-RuizABeiras-FernandezALehmkuhlHClinical experience with daptomycin in Europe: the first 2.5 yearsJ Antimicrob Chemother201166491291921393205
   PubMed Web of Science ®Google Scholar
• OwensRCJrLampKFriedrichLVPostmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycinAm J Med200712010 Suppl 1S6S1217904950
   PubMed Web of Science ®Google Scholar
• BrownJLampKCFriedrichLEfficacy and safety of daptomycin for the treatment of skin and skin structure infections (SSSI)Abstracts of the Fourth International Symposium on Resistant Gram-positive InfectionsOntario, Canada2006 Abstract CPLA27.
   Google Scholar
• KatzDEMartoneWJcSSTIs with culture confirmed Staphylococcus aureus treated with daptomycin: Cubicin Outcome Registry and Experience (CORE) 2005 Interim AnalysisAbstracts of the 2006 Annual Conference on Antimicrobial Resistance2006 June 26–28Bethesda, MD Poster 22:25. National Foundation for Infectious Diseases, Bethesda, MD.
   Google Scholar
• LampKCFriedrichLLindfieldKClinical factors associated with daptomycin outcomes in skin and soft-tissue infectionsAbstracts of the Seventeenth European Congress of Clinical Microbiology and Infectious Diseases2007 March 31–April 3Munich, Germany Poster 837: S213 European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland
   Google Scholar
• CogoADialianaZGargalianos-KakolyrisPComplicated skin and soft tissue infections (cSSTIs) treated with daptomycin in the European Cubicin Outcomes Registry and Experience (EU-CORE)Abstracts from the 20th ECCMID (European Congress of Clinical Microbiology and Infectious Diseases)2010 April 10–13Vienna, Austria Poster 1227.
   Google Scholar
• RolstonKVSegretiJLampKCFriedrichLVCubicin Outcomes Registry and Experience (CORE) methodologyAm J Med200712010 Suppl 1S4S517904949
   PubMed Web of Science ®Google Scholar
• SakoulasGBrownJLampKFriedrichLVLindfieldKCClinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and ExperienceClin Ther20093191936194519843483
   PubMed Web of Science ®Google Scholar
• BertoniAGSaydahSBrancatiFLDiabetes and the risk of infection-related mortality in the USDiabetes Care20012461044104911375368
   PubMed Web of Science ®Google Scholar
• ChamberlainRSCulshawDLDonovanBJLampKCDaptomycin for the treatment of surgical site infectionsSurg20091462316324
   Web of Science ®Google Scholar
• PfallerMASaderHSJonesRNEvaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002–2005)Diagn Microbiol Infect Dis200757445946517240105
   PubMed Web of Science ®Google Scholar
• CastanheiraMJonesRNSaderHSUpdate of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)Diagn Microbiol Infect Dis200861223523918314293
   PubMed Web of Science ®Google Scholar
• SaderHSFarrellDJJonesRNAntimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centersInt J Antimicrob Agents2010361283220444576
   PubMed Web of Science ®Google Scholar
• SaderHSMoetGJonesRNUpdate on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005–2007)J Chemother200921550050619933040
   PubMed Web of Science ®Google Scholar
• BellJMTurnidgeJDSaderHSJonesRNAntimicrobial activity and spectrum of daptomcyin: results from the surveillance program in Australia and New Zealand (2008)Pathology201042547047320632825
   PubMed Web of Science ®Google Scholar
• GalesACSaderHSRibeiroJZoccoliCBarthAPignatariACAntimicrobial susceptibility of Gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005–2008)Braz J Infect Dis2009132909820140350
   PubMed Web of Science ®Google Scholar
• LipskyBAStoutenburghUDaptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infectionsJ Antimicrob Chemother200555224024515659542
   PubMed Web of Science ®Google Scholar
• MartoneWJLindfieldKCKatzDEOutpatient parenteral antibiotic therapy with daptomycin: insights from a patient registryInt J Clin Pract20086281183118718705821
   PubMed Web of Science ®Google Scholar
• SeatonRACoiaJMastertonRMRSA complicated skin and skin structure infections in Glasgow: evaluation of hospital management and potential for earlier dischargeAbstracts from the 20th European Congress of Clinical Microbiology and Infectious Diseases2010 April 10–13Vienna, Austria Poster 1873.
   Google Scholar
• SeatonRABellEGourlayYSempleLNurse-led management of uncomplicated cellulitis in the community; evaluation of a protocol incorporating intravenous ceftriaxoneJ Antimicrob Chemother200555576476715772137
   PubMed Web of Science ®Google Scholar
• LamontESeatonRAMacphersonMSempleLBellEThomsonAHDevelopment of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programmeJ Antimicrob Chemother200964118118719411678
   PubMed Web of Science ®Google Scholar
• SeatonRABellEBezlyakVFactors associated with outcome and length of parenteral therapy in outpatient parenteral antibiotic therapy (OPAT) treated patients with skin and soft tissue infections (SSTIs)Abstracts from the 19th European Congress Clinical Microbiology and Infectious Diseases2010 April 10–13Vienna, Austria Poster 1333.
   Google Scholar
• SeatonRAGonzalez-RamalloVJPriscoVDaptomycin for out-patient parenteral antibiotic therapy (OPAT), a European registry experienceAbstracts from the 7th International Conference of the Hospital Infection Society2010 October 10–13Liverpool, UK Poster 01.06.
   Google Scholar
• HuangYHsiaoCLiaoCLeeCWHsuehPRBacteraemia and infective endocarditis cuased by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in TaiwanJ Clin Microbiol20084631132113618199793
   PubMed Web of Science ®Google Scholar
• HaydenMKRezaiKHayesRALolandKQuinnJPWeinsteinRADevelopment of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureusJ Clin Microbiol200543105285528716207998
   PubMed Web of Science ®Google Scholar
• CuiLTominagaENeohHMCorrelation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureusAntimicrob Agents Chemother20065031079108216495273
   PubMed Web of Science ®Google Scholar
• SakoulasGAlderJThauvin-EliopoulosCMoelleringRCJrEliopoulosGMInduction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycinAntimicrob Agents Chemother20065041581158516569891
   PubMed Web of Science ®Google Scholar
• SaderHSBeckerHKMoetGJJonesRNAntimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006–2008)Diagn Microbiol Infect Dis201066332933120159377
   PubMed Web of Science ®Google Scholar
• MoisePAHershbergerEAmodio-GrotonMILampKCSafety and clinical outcomes when utilising high-dose (≥8 mg/kg) daptomycin therapyAnn Pharmacother20094371211121919584384
   PubMed Web of Science ®Google Scholar
• CunhaBAEisensteinLEHamidNSPacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteraemia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicityHeart Lung200635320721116701116
   PubMed Web of Science ®Google Scholar
• LampKCFriedrichLVMedez-VigoLRussoRClinical experience with daptomycin for the treatment of patients with osteomyelitisAm J Med200712010 Suppl 1S13S2017904946
   PubMed Web of Science ®Google Scholar
• MohrIII JFOstrosky-ZeichnerLWainrightDJParksDHHollenbeckTCEricssonCDPharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injuryAntimicrob Agents Chemother20085251891189318299410
   PubMed Web of Science ®Google Scholar
• GoetghebeurMLandryPAHanDVicenteCMethicillin-resistant Staphylococcus aureus: a public health issue with economic consequencesCan J Infect Dis Med Microbiol2007181273418923684
   PubMed Web of Science ®Google Scholar
• FossacecaCOutcomes analysis of daptomycin use in a community hospitalAdv Ther200724351752817660160
   PubMed Web of Science ®Google Scholar
• NathwaniDMorganMMastertonRGGuidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the communityJ Antimicrob Chemother200861597699418339633
   PubMed Web of Science ®Google Scholar
• MensaJBarberanJLlinaresPGuidelines for the treatment of infections caused by methicillin-resistant Staphylococcus aureusRev Esp Quimioter200821423425819031124
   PubMed Web of Science ®Google Scholar